1
|
van Kraaij SJW, Hamblin MR, Pickering G, Giannokopoulos B, Kechemir H, Heinz M, Igracki-Turudic I, Yavuz Y, Rissmann R, Gal P. A Phase 1 randomized, open-label clinical trial to evaluate the effect of a far-infrared emitting patch on local skin perfusion, microcirculation and oxygenation. Exp Dermatol 2024; 33:e14962. [PMID: 37950549 DOI: 10.1111/exd.14962] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 09/06/2023] [Accepted: 10/06/2023] [Indexed: 11/12/2023]
Abstract
Far-infrared radiation (FIR) has been investigated for reduction of pain and improvement of dermal blood flow. The FIRTECH patch is a medical device designed to re-emit FIR radiated by the body. This phase 1 study was conducted to evaluate the local effects of the FIRTECH patch on local skin perfusion, microcirculation and oxygenation. This prospective, randomized, open-label, parallel designed study admitted 20 healthy participants to a medical research facility for treatment for 31 h on three anatomical locations. During treatment, imaging assessments consisting of laser speckle contrast imaging, near-infrared spectroscopy, side-stream dark-field microscopy, multispectral imaging and thermography were conducted regularly on patch-treated skin and contralateral non-treated skin. The primary endpoint was baseline perfusion increase during treatment on the upper back. Secondary endpoints included change in baseline perfusion, oxygen consumption and temperature of treated versus untreated areas. The primary endpoint was not statistically significantly different between treated and non-treated areas. The secondary endpoints baseline perfusion on the forearm (least square means [LSMs] difference 2.63 PU, 95% CI: 0.97, 4.28), oxygen consumption (LSMs difference: 0.42 arbitrary units [AUs], 95% CI: 0.04, 0.81) and skin temperature (LSMs difference 0.35°C, 95% CI: 0.16, 0.6) were statistically significantly higher in treated areas. Adverse events observed during the study were mild and transient. The vascular response to the FIRTECH patch was short-lived suggesting a non-thermal vasodilatory effect of the patch. The FIRTECH patch was well tolerated, with mild and transient adverse events observed during the study. These results support the therapeutic potential of FIR in future investigations.
Collapse
Affiliation(s)
- Sebastiaan J W van Kraaij
- Centre for Human Drug Research, Leiden, the Netherlands
- Leiden University Medical Centre, Leiden, the Netherlands
| | - Michael R Hamblin
- Laser Research Centre, Faculty of Health Science, University of Johannesburg, Johannesburg, South Africa
| | - Gisele Pickering
- Clinical Investigation Center CIC Inserm 1405, University Hospital Clermont-Ferrand, Clermont-Ferrand, France
| | | | | | - Moritz Heinz
- Research & Development, Sanofi, Chilly-Mazarin, France
| | | | - Yalçin Yavuz
- Centre for Human Drug Research, Leiden, the Netherlands
| | - Robert Rissmann
- Centre for Human Drug Research, Leiden, the Netherlands
- Leiden Academic Centre for Drug Research, Leiden, the Netherlands
| | - Pim Gal
- Centre for Human Drug Research, Leiden, the Netherlands
- Leiden University Medical Centre, Leiden, the Netherlands
| |
Collapse
|
2
|
Huang J, Zheng P, Chen X, Zheng F, He B. Effect of far-infrared therapy device on arteriovenous fistula maturation and lifespan in hemodialysis patients: a randomized controlled clinical trial. Front Surg 2023; 10:1260979. [PMID: 37753529 PMCID: PMC10518414 DOI: 10.3389/fsurg.2023.1260979] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Accepted: 08/11/2023] [Indexed: 09/28/2023] Open
Abstract
Introduction Arteriovenous fistula (AVF) is the first choice of vascular access for hemodialysis treatment, and its surgical maturity rate is not high, and its postoperative complications (mostly stenosis) significantly shorten its life. At present, there are few studies on treatment methods to improve the maturity and survival of AVF. In this study, the effect of far infrared therapy (FIR) on the maturity and longevity of arteriovenous fistula in hemodialysis patients was discussed, and the protective mechanism of AVF induced by FIR therapy was explored, aiming at exploring a new treatment method. Methods The hemodialysis patients admitted to the 900th Hospital of the Chinese Joint Logistics Support Force of the People's Liberation Army from January 2021 to April 2023 were randomly divided into control group and intervention group, with 40 cases in each group. Among them, the control group was coated with mucopolysaccharide polysulfonate cream; Intervention group: The patients were treated with mucopolysaccharide polysulfonate cream and far infrared radiation at the same time. After 3 months' intervention, the arteriovenous fistula (vein diameter, mature time of arteriovenous fistula, blood flow controlled by pump during dialysis, blood flow of brachial artery during dialysis and the occurrence of complications of internal fistula (oozing, occlusion and infection) and the pain score (numerical rating scale, NRS) of the two groups were compared, and the curative effects were compared. Results There was no significant difference in general data between the two groups (P > 0.05), which indicated that the study was comparable. After 3 months' intervention, the vein diameter, pump-controlled blood flow and brachial artery blood flow in the intervention group were significantly higher than those in the control group (P < 0.05). And the maturity time, NRS score and complication rate of arteriovenous fistula were significantly lower than those of the control group (P < 0.05). The primary patency rate of AVF in the intervention group was higher than that in the control group, and the overall patency rate between the two groups was statistically significant (P < 0.05). Conclusions As a promising new treatment method, far infrared therapy can effectively promote the maturity of AVF, increase venous diameter, pump controlled blood flow during dialysis, brachial artery blood flow during dialysis, and prolong the service life of AVF.
Collapse
Affiliation(s)
- Jianqiang Huang
- Department of General Surgery, No. 900th Hospital of China People's Liberation Army Joint Logistics Support Force, Fuzhou, China
| | - Peilan Zheng
- Department of Nephrology, No. 900th Hospital of China People's Liberation Army Joint Logistics Support Force, Fuzhou, China
| | - Xiaobin Chen
- Department of General Surgery, No. 900th Hospital of China People's Liberation Army Joint Logistics Support Force, Fuzhou, China
| | - Fan Zheng
- Department of General Surgery, No. 900th Hospital of China People's Liberation Army Joint Logistics Support Force, Fuzhou, China
| | - Beibei He
- Department of General Surgery, No. 900th Hospital of China People's Liberation Army Joint Logistics Support Force, Fuzhou, China
| |
Collapse
|
3
|
Hansen EK, Lindhard K, Hansen D. Acute hemodynamic changes during far infrared treatment of the arteriovenous fistula in hemodialysis patients. J Vasc Access 2023; 24:739-746. [PMID: 34715757 DOI: 10.1177/11297298211052864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND The arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis (HD) treatment and preservation of a stable vascular access is crucial. Long term Far Infrared Radiation (FIR) has been found to increase access flow together with an enhanced maturation and patency of the AVF. The acute effects of FIR on access flow have been sparsely described and the results are contradictory, perhaps due to differences in measurement conditions and other factors of importance for access flow. METHODS Twenty patients in HD with an AVF were included. Each patient was randomized to receive either FIR (FIR group) or no FIR (control group). The acute changes in access flow were investigated in both groups on the second dialysis day of the week and during the first 1.5 h of the dialysis session. Concomitant changes in hemodynamic parameters of importance for access flow were also explored. RESULTS There was no significant change in access flow in the FIR group compared with the control group (median (Interquartile Range)) (-10 (-413.8; 21.3) ml/min vs -17.5 (-83.8; 76.3) ml/min, p = 0.58). There was no significant difference in any of the hemodynamic parameters between the FIR and the control group; cardiac output (-0.7 (-1.2; -0.2) l/min vs -0.4 (-0.9; 0.1) l/min, p = 0.58), cardiac index (-0.3 (-0.5; -0.1)) l/min/m2 vs -0.3 (-0.4; 0) l/min/m2, p = 0.68), mean arterial pressure (5.5 (-1.8; 8.4) mmHg vs 1.5 (-3; 6.3) mmHg, p = 0.35) and total peripheral resistance (2 (1.8; 3.4) mmHg × min/l vs 1 (-0.3; 3.1) mmHg × min/l, p = 0.12). CONCLUSION In this trial, with a highly standardized set-up, one session of FIR did not result in any acute changes in access flow. This was not due to differences in the hemodynamic parameters between the groups.
Collapse
Affiliation(s)
| | | | - Ditte Hansen
- Department of Nephrology, Herlev Hospital, Herlev, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Science, University of Copenhagen, Denmark
| |
Collapse
|
4
|
Lindhard K, Rix M, Heaf JG, Hansen HP, Pedersen BL, Jensen BL, Hansen D. Effect of far infrared therapy on arteriovenous fistula maturation, survival and stenosis in hemodialysis patients, a randomized, controlled clinical trial: the FAITH on fistula trial. BMC Nephrol 2021; 22:283. [PMID: 34419006 PMCID: PMC8379732 DOI: 10.1186/s12882-021-02476-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Accepted: 07/12/2021] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND An arteriovenous fistula (AVF) is the preferred vascular access for hemodialysis treatment. After creation many of the AVFs will never mature or if functioning will need an intervention within 1 year due to an AVF stenosis. Studies investigating possible therapies that improves the AVF maturation and survival are scarce. Far infrared therapy (FIR) has shown promising results. In minor single centre and industry supported trials FIR has shown improved AVF maturation and survival. There is a need of a randomized multicentre controlled trial to examine the effect of FIR on the AVF maturation and survival and to explore the possible AVF protective mechanism induced by the FIR treatment. METHODS This investigator initiated, randomized, controlled, open-labeled, multicenter clinical trial will examine the effect of FIR on AVF maturation in patients with a newly created AVF (incident) and AVF patency rate after 1 year of treatment in patients with an existing AVF (prevalent) compared to a control group. The intervention group will receive FIR to the skin above their AVF three times a week for 1 year. The control group will be observed without any treatment. The primary outcome for incident AVFs is the time from surgically creation of the AVF to successful cannulation. The primary outcome for the prevalent AVFs is the difference in number of AVFs without intervention and still functioning in the treatment and control group after 12 months. Furthermore, the acute changes in inflammatory and vasodilating factors during FIR will be explored. Arterial stiffness as a marker of long term AVF patency will also be examined. DISCUSSION FIR is a promising new treatment modality that may potentially lead to improved AVF maturation and survival. This randomized controlled open-labelled trial will investigate the effect of FIR and its possible mechanisms. TRIAL REGISTRATION Clinicaltrialsgov NCT04011072 (7th of July 2019).
Collapse
Affiliation(s)
- K Lindhard
- Department of Nephrology, Herlev Hospital, Borgmester Ib Juels Vej 1, DK-2730, Herlev, Denmark.
| | - M Rix
- Department of Nephrology, Rigshospitalet, Copenhagen, Denmark
| | - J G Heaf
- Department of Nephrology, University hospital of Zealand, Roskilde, Denmark
| | - H P Hansen
- Department of Nephrology, Herlev Hospital, Borgmester Ib Juels Vej 1, DK-2730, Herlev, Denmark
| | - B L Pedersen
- Department of Vascular Surgery, Rigshospitalet, Copenhagen, Denmark
| | - B L Jensen
- Department of cardiovascular and renal research, University Hospital of Southern Denmark, Odense, Denmark
| | - D Hansen
- Department of Nephrology, Herlev Hospital, Borgmester Ib Juels Vej 1, DK-2730, Herlev, Denmark
| |
Collapse
|
5
|
Lee HS, Kim SG. A Korean perspective on the 2019 Kidney Disease Outcomes Quality Initiative guidelines for vascular access: what has changed and what should be changed in practice? Kidney Res Clin Pract 2021; 40:29-39. [PMID: 33653020 PMCID: PMC8041626 DOI: 10.23876/j.krcp.20.144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Accepted: 10/30/2020] [Indexed: 11/25/2022] Open
Abstract
The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines are developed by the National Kidney Foundation in the United States; however, the guidelines have an impact on most international societies, including those in Korea. The KDOQI recently released the updated 2019 guidelines for vascular access based on numerous papers and controversies concerning vascular access since 2006, when the first guidelines were published. The new KDOQI guidelines have undergone significant changes compared to previous guidelines, including a change in the philosophy regarding a patient-centered approach using an end-stage kidney disease “Life-Plan.” In addition, there are newly developed or revised definitions and some key differences from previous guidelines. The process of adapting guidelines needs to be individualized to hemodialysis practice in each country, while agreeing with general principles and philosophy; therefore, we summarize changes in the updated guidelines and discuss the application and implementation of the new principles and concepts of the guidelines for vascular access care in Korea.
Collapse
Affiliation(s)
- Hyung Seok Lee
- Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea
| | - Sung Gyun Kim
- Division of Nephrology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea
| |
Collapse
|
6
|
Anand SM, Fernando ME, Suhasini B, Valarmathi K, Elancheralathan K, Srinivasaprasad ND, Sujit S, Thirumalvalavan K, Prabhakaran CA, Jeyashree K. The Role of Far Infrared Therapy in the Unassisted Maturation of Arterio-venous Fistula in Patients with Chronic Kidney Disease. Indian J Nephrol 2020; 30:307-315. [PMID: 33707817 PMCID: PMC7869642 DOI: 10.4103/ijn.ijn_122_19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 05/28/2019] [Accepted: 06/14/2019] [Indexed: 12/04/2022] Open
Abstract
Introduction: The goal of arterio-venous fistula (AVF) creation is to achieve a well-functioning access that can be cannulated repetitively and can provide adequate flow for the dialysis. The objective of this study was to assess the role of far infrared (FIR) therapy in the unassisted maturation of newly created AVF in patients with chronic kidney disease (CKD). Materials and Methods: In this prospective open labeled randomised control trial, 107 patients were randomized. Participants in the control arm received oral clopidogrel 75 mg once daily for 30 days along with isometric hand exercise, whereas those in the test arm received FIR therapy twice weekly, 40 min session each, for 4 weeks. A biopsy from venous end was taken during fistula surgery. Doppler study of AVF was done at the end of the 4th and 12th week to assess AVF. Vascular access guidelines proposed by National Kidney Foundation –Kidney Disease Outcomes Quality Initiative (NKF- KDOQI) in 2006 were adapted to define the maturation of AVF. Results: Out of 107 patients, 51 were randomized to the test arm and 56 to the control arm. During follow-up, the blood flow rate through AVF (Qa) and the diameter of the cephalic vein draining (CVd) the AVF were measured. At the end of 3 months, Qa in Radio-Cephalic Fistula (RCF) was high in the test arm (p–0.003). The AVF failures were 5 (10.2%) and 14 (28%) in the test and control arms, respectively (p: 0.025). However, when adjusted for AVF failure within 6 h of surgery (may be related to surgical technique) this difference in AVF patency was statistically insignificant (p: 0.121). The mean Qa was high in patients with an arterial intimal medial thickness (AIMT) <0.5 mm. The IMT of the anastomosed artery had statistically significant correlation with the primary failure rate of AVF (P < 0.001). Conclusion: In patients with CKD, FIR therapy was effective in increasing the AVF blood flow rate at the end of 3 months, though the difference in primary failure rate was statistically insignificant.
Collapse
Affiliation(s)
- S Murugesh Anand
- Department of Nephrology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - M Edwin Fernando
- Department of Nephrology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - B Suhasini
- Department of Radio-Diagnosis, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - K Valarmathi
- Department of Pathology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - K Elancheralathan
- Vascular Surgery, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - N D Srinivasaprasad
- Department of Nephrology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - S Sujit
- Department of Nephrology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - K Thirumalvalavan
- Department of Nephrology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - C Arun Prabhakaran
- Department of Pathology, Government Stanley Medical College and Hospital, Chennai, Tamil Nadu, India
| | - K Jeyashree
- Department of Community Medicine, Velammal Medical College Hospital, Madurai, Tamil Nadu, India
| |
Collapse
|
7
|
Tsai WC, Chiang WH, Wu CH, Li YC, Campbell M, Huang PH, Lin MW, Lin CH, Cheng SM, Chang PC, Cheng CC. miR-548aq-3p is a novel target of Far infrared radiation which predicts coronary artery disease endothelial colony forming cell responsiveness. Sci Rep 2020; 10:6805. [PMID: 32322002 PMCID: PMC7176637 DOI: 10.1038/s41598-020-63311-1] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2019] [Accepted: 03/21/2020] [Indexed: 12/24/2022] Open
Abstract
Non-invasive far infrared radiation (FIR) has been observed to improve the health of patients with coronary artery disease (CAD). Endothelial colony forming cells (ECFCs) contribute to vascular repair and CAD. The goal of this study was to uncover the role of FIR in ECFCs function and to reveal potential biomarkers for indication of FIR therapy in CAD patients. FIR significantly enhanced in vitro migration (transwell assay) and tube formation (tube length) capacities in a subpopulation of CAD ECFCs. Clinical parameters associated with the responsiveness of ECFCs to FIR include smoking and gender. ECFCs from CAD patients that smoke did not respond to FIR in most cases. In contrast, ECFCs from females showed a higher responsiveness to FIR than ECFCs from males. To decipher the molecular mechanisms by which FIR modulates ECFCs functions, regardless of sex, RNA sequencing analysis was performed in both genders of FIR-responsive and FIR-non/unresponsive ECFCs. Gene Ontology (GO) analysis of FIR up-regulated genes indicated that the pathways enriched in FIR-responsive ECFCs were involved in cell viability, angiogenesis and transcription. Small RNA sequencing illustrated 18 and 14 miRNAs that are up- and down-regulated, respectively, in FIR-responsive CAD ECFCs in both genders. Among the top 5 up- and down-regulated miRNAs, down-regulation of miR-548aq-3p in CAD ECFCs after FIR treatment was observed in FIR-responsive CAD ECFCs by RT-qPCR. Down-regulation of miR-548aq-3p was correlated with the tube formation activity of CAD ECFCs enhanced by FIR. After establishment of the down-regulation of miR-548aq-3p by FIR in CAD ECFCs, we demonstrated through overexpression and knockdown experiments that miR-548aq-3p contributes to the inhibition of the tube formation of ECFCs. This study suggests the down-regulation of miR-548aq-3p by FIR may contribute to the improvement of ECFCs function, and represents a novel biomarker for therapeutic usage of FIR in CAD patients.
Collapse
Affiliation(s)
- Wei-Che Tsai
- Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.,Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan
| | - Wei-Hui Chiang
- Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan
| | - Chun-Hsien Wu
- Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.,Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan
| | - Yue-Cheng Li
- Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan
| | - Mel Campbell
- UC Davis Cancer Center, University of California, Davis, California, USA
| | - Po-Hsun Huang
- Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan.,Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital and Institute of Clinical Medicine, Taipei, Taiwan
| | - Ming-Wei Lin
- Institute of Public Health, National Yang-Ming University, Taipei, 112, Taiwan
| | - Chi-Hung Lin
- Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan.,Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
| | - Shu-Meng Cheng
- Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
| | - Pei-Ching Chang
- Institute of Microbiology and Immunology, National Yang-Ming University, Taipei, Taiwan. .,Cancer Progression Research Center, National Yang-Ming University, Taipei, Taiwan.
| | - Cheng-Chung Cheng
- Division of Cardiology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
| |
Collapse
|
8
|
Chang Y. The effect of far infrared radiation therapy on inflammation regulation in lipopolysaccharide-induced peritonitis in mice. SAGE Open Med 2018; 6:2050312118798941. [PMID: 30210795 PMCID: PMC6131272 DOI: 10.1177/2050312118798941] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2018] [Accepted: 08/13/2018] [Indexed: 11/27/2022] Open
Abstract
Objective: Far infrared radiation has been widely used in a variety of healthcare
institutions and clinical research. Previous studies have shown that far
infrared radiation can promote blood circulation and enhance the functioning
of the immune system. Many patients receiving peritoneal dialysis have been
co-treated with far infrared radiation to reduce the occurrence of
inflammation. This study seeks to evaluate the effects of far infrared
radiation therapy on inflammation. Method: We used the lipopolysaccharide-induced peritonitis mouse model to study the
effect of far infrared radiation treatment. Sixteen mice were randomly
divided into two groups, a far infrared radiation treatment group
(n = 8) and a non-far infrared radiation treatment
group (n = 8). Collected blood samples were studied by
analyzing the RNA level of peripheral blood mononuclear cells and the plasma
protein levels of interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α),
and endothelial nitric oxide synthase (eNOS). Results: The administration of far infrared radiation inhibited the RNA levels of
interleukin-6 and TNF-α after stimulation by lipopolysaccharide. The far
infrared radiation treatment inhibited the endothelial nitric oxide synthase
RNA levels at 1 h, but the RNA levels returned close to the baseline level
after 2 h. In the control group, the endothelial nitric oxide synthase RNA
levels were continuously decreasing. The interleukin-6 concentration in the
plasma of the far infrared radiation group showed significant inhibition
30 min after lipopolysaccharide stimulation. The tumor necrosis factor alpha
RNA concentration in plasma of the far infrared radiation group was
significantly reduced 2 h after lipopolysaccharide stimulation. Conclusion: Far infrared radiation therapy can inhibit interleukin-6 and tumor necrosis
factor alpha RNA levels of peripheral blood mononuclear cells and recover
endothelial nitric oxide synthase expression. These results demonstrate that
far infrared radiation therapy might aid in reducing the level of
inflammation experienced by patients going through peritoneal dialysis
treatment.
Collapse
Affiliation(s)
- Yuanmay Chang
- Institute of Long-Term Care, MacKay Medical College, New Taipei City, Taiwan.,Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
| |
Collapse
|
9
|
Wan Q, Yang S, Li L, Chu F. Effects of far infrared therapy on arteriovenous fistulas in hemodialysis patients: a meta-analysis. Ren Fail 2018; 39:613-622. [PMID: 28805538 PMCID: PMC6446143 DOI: 10.1080/0886022x.2017.1361835] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
Background: Far infrared (FIR) therapy may have a beneficial effect on maturity and function of arteriovenous fistulas (AVFs) in hemodialysis (HD) patients. Therefore, we performed this pooled analysis to assess the protective effects of FIR therapy in HD patients. Methods: The randomized controlled trials (RCTs) and quasi-RCTs of FIR therapy for HD patients were searched from multiple databases. Relevant studies were screened according to the predefined inclusion criteria. The meta-analyses were performed using RevMan 5.2 software (The Cochrane Collaboration, Oxford, UK). Results: Meta-analysis showed that FIR therapy could significantly increase the vascular access blood flow level (MD, 81.69 ml/min; 95% CI, 46.17–117.21; p < .001), AVFs diameter level (MD, 0.36 mm; 95% CI, 0.22–0.51; p < .001), and the primary AVFs patency (pooled risk ratio = 1.24; 95% CI, 1.12–1.37, p < .001). In addition, therapy with FIR ray radiation could decrease AVFs occlusion rates (pooled risk ratio = 0.20; 95% CI, 0.08–0.46; p < .001) and the level of needling pain (pooled risk ratio = 0.08; 95% CI, 0.06–0.10, p < .001). Conclusions: FIR therapy can reduce AVFs occlusion rates and needling pain level, while significantly improve the level of vascular access blood flow, AVFs diameter and the primary AVFs patency.
Collapse
Affiliation(s)
- Qingsong Wan
- a Department of Nephrology , The First Affiliated Hospital of the University of South China , Hengyang , Hunan Province , China
| | - Shikun Yang
- b Department of Nephrology , The Third Xiangya Hospital of Central South University , Changsha , Hunan Province , China
| | - Li Li
- c Department of Medicine , Hunan Environment biological Polytechnic , Hengyang , Hunan Province , China
| | - Fenfen Chu
- a Department of Nephrology , The First Affiliated Hospital of the University of South China , Hengyang , Hunan Province , China
| |
Collapse
|